International ABOUT PRODUCTS RESEARCH & DEVELOPMENT INVESTORS NEWS CAREERS CONTACT CUSTOMER LOGIN Our Milestones We are building a stronger, more capable Amneal We have made dramatic progress in growing Amneal from a family start-up in 2002 to our current status as a diversified, publicly-held (NYSE: AMRX) pharmaceutical company. Milestones and achievements highlight our progress, deepen our impact and demonstrate our passion for making healthy possible. 2002 Amneal founded Amneal opens its doors in Paterson, New Jersey. 2005 Manufactures first Rx product Files first ANDA Amneal begins manufacturing folic acid, its first prescription product. The company also files its first ANDA as Amneal Pharmaceuticals. 2006 First ANDA approved The first ANDA prepared and submitted by Amneal is approved (Metformin 500, 850 & 1000mg tablets) 2007 Acquires ANDAs from Merck Acquires ANDAs and facility from KVD Acquires Akyma and launches Amneal label Amneal acquires a liquid Rx manufacturing/R&D plant in Branchburg, New Jersey, along with multiple ANDAs and product development IP from KVD. That same year, the company acquires all assets related to five generic drugs divested by Merck KGaA and launches the Amneal label, going directly to market via its acquisition of Akyma. 2008 Acquires InterPharm Opens India R&D center Amneal purchases Interpharm assets, including over 240,000 sq. ft. of manufacturing/R&D capacity in New York. Later that year, celebrates the grand opening of its 75,000 sq. ft. R&D center, Amneal India. 2009 Becomes 12th largest generics company in the U.S. (in TRx) IMS Health shows Amneal Pharmaceuticals as the 12th largest generics supplier in the U.S., by number of prescriptions dispensed. This same study highlights 114% year-over-year growth of the company. 2010 Opens consolidated, expanded distribution & sales operations in Glasgow, Kentucky Acquires manufacturing facility in Piscataway, New Jersey Amneal opens a 115,000 sq. ft. consolidated distribution and sales logistics center in Glasgow, Kentucky. The company also acquires a state-of-the-art R&D and manufacturing plant in Piscataway, New Jersey, allowing further expansion into new technologies and complex, niche products. 2011 Acquires packaging facility in East Hanover, New Jersey Becomes the 7th largest generics company in the U.S. (in TRx) IMS Health lists Amneal as the 7th largest generics company in prescriptions dispensed. Amneal acquires a 110,000 sq. ft. packaging plant in East Hanover, New Jersey to support its tremendous growth. 2012 FDA approves new API and FDF facilities in India The U.S. FDA inspects and approves two Amneal facilities in India — one for manufacturing active pharmaceutical ingredients (API) and the other finished dosage-forms. 2013 Acquires 1000+ MAs from Pfizer Acquires assets from Actavis and Warner Chilcott Acquires 60% of Creo Pharma Creo Pharma in the United Kingdom is the first of many international transactions for Amneal. Creo supplies generic pharmaceuticals, commercial brands and specialist products to the pharmacy, hospital and wholesale sectors in the U.K. 2014 Acquires CoPharma Acquires Pharmagenus Acquires Bioeq Opens International HQ To oversee its expanding global operations, Amneal opens its international headquarters in Zug, Switzerland. 2015 Acquires Actavis Australia Acquires Epsilon India Acquires inhalation manufacturing site in Ireland Amneal adds to its international operations with acquisitions in Australia, India and Ireland. The 200,000 sq. ft. manufacturing facility in Cashel, County Tipperary in Ireland, is dedicated to R&D and the production of metered dose and dry powder inhalers (MDIs and DPIs) as well as biosimilars. 2016 Adds distribution facility in Glasgow, Kentucky Amneal adds another distribution center in Glasgow, KY. 2017 Completes expansion of both New York manufacturing facilities Divests Amneal Australia operation Divests CoPharma and Pharmagenus operations Expansion of the Amneal plant in Brookhaven, New York took the facility from 120,000 sq ft to 600,000 sq ft. in 2017. 2018 Amneal and Impax Laboratories combine to form a more diversified, publicly traded Amneal (NYSE:AMRX) Combination expands generics portfolio, pipeline and adds specialty business 2019 Formally opened our new 81,100 square foot distribution facility in Glasgow, Kentucky Expanded our Specialty CNS pipeline by signing licensing agreement with Kashiv BioSciences, LLC for the development and commercialization of orphan drug K-127 (pyridostigmine) for the treatment of Myasthenia Gravis Announced definitive agreement to acquire majority interest in AvKARE, one of the largest private label providers of generic pharmaceuticals in the U.S. federal agency sector 2020 Completed acquisition of majority interest in AvKARE, business begins operating as an independent subsidiary of Amneal serving the federal healthcare market Implemented sweeping COVID-19 response plan focused on prioritizing employee health and business continuity. Supported U.S. government’s request for medicines during COVID-19 pandemic 2021 Announced agreement to acquire substantially all of Kashiv Specialty Pharmaceuticals, LLC – expected to deliver substantial value for our Specialty and Generics businesses Privacy Notice Privacy Shield Copyright & Legal Disclaimer Web Accessibility Linkedin NABP DDA Accreditation © 2021 Amneal Pharmaceuticals LLC. All rights reserved. We use cookies for statistical and measurement purposes, to help improve our website and to allow us and our partners to provide you with more relevant information. By continuing to navigate this site, closing this box, or by clicking here you are indicating your consent to our use of cookies. To find out more, including how to withdraw your consent, click here ACCEPTREFUSE